$278.11
0.11% today
NYSE, Apr 23, 07:44 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$278.40
-35.98 11.44% 1M
-41.26 12.91% 6M
+17.76 6.81% YTD
+6.49 2.39% 1Y
+28.05 11.20% 3Y
+49.11 21.42% 5Y
+109.30 64.64% 10Y
NYSE, Closing price Tue, Apr 22 2025
+4.72 1.72%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Market capitalization $149.68b
Enterprise Value $198.59b
P/E (TTM) P/E ratio 36.89
EV/FCF (TTM) EV/FCF 19.11
EV/Sales (TTM) EV/Sales 5.98
P/S ratio (TTM) P/S ratio 4.50
P/B ratio (TTM) P/B ratio 25.43
Dividend yield 3.23%
Last dividend (FY24) $9.00
Revenue growth (TTM) Revenue growth 18.64%
Revenue (TTM) Revenue $33.23b
EBIT (operating result TTM) EBIT $8.73b
Free Cash Flow (TTM) Free Cash Flow $10.39b
Cash position $11.97b
EPS (TTM) EPS $7.55
P/E forward 23.34
P/S forward 4.26
EV/Sales forward 5.65
Short interest 2.62%
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Amgen forecast:

13x Buy
42%
15x Hold
48%
3x Sell
10%

Analyst Opinions

31 Analysts have issued a Amgen forecast:

Buy
42%
Hold
48%
Sell
10%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
33,232 33,232
19% 19%
100%
- Direct Costs 11,282 11,282
33% 33%
34%
21,950 21,950
12% 12%
66%
- Selling and Administrative Expenses 1,693 1,693
32% 32%
5%
- Research and Development Expense 5,938 5,938
24% 24%
18%
14,319 14,319
17% 17%
43%
- Depreciation and Amortization 5,592 5,592
37% 37%
17%
EBIT (Operating Income) EBIT 8,727 8,727
6% 6%
26%
Net Profit 4,090 4,090
39% 39%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Neutral
Barrons
one day ago
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Positive
The Motley Fool
one day ago
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.
Positive
FXEmpire
2 days ago
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 28,000
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today